Abarelix Side Effects: Safety Signals and Warnings
Abarelix safety concerns are compound-specific. The main listed side effects are Immediate-onset allergic reactions (3.7%), Hot flashes, and Sleep disturbances. The main warning signals are Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring, Available only through restricted distribution program due to allergy risk, and Bone density loss with prolonged androgen deprivation.
Direct Answer
Abarelix has historical FDA approval but is no longer marketed in the United States. Its immediate systemic allergic-reaction risk sharply limited use, and currently available GnRH antagonists have replaced it. It is a historical pharmacology reference, not a current treatment option.
- Evidence grade
- Level A
- Research status
- Historical FDA Approval
- Category
- Sexual Health
- Evidence context
- Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols
Reported Side Effects
- Immediate-onset allergic reactions (3.7%)
- Hot flashes
- Sleep disturbances
- Breast enlargement
- Pain at injection site
- Constipation
- Peripheral edema
- Fatigue
Warnings
- Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring
- Available only through restricted distribution program due to allergy risk
- Bone density loss with prolonged androgen deprivation
- Cardiovascular and metabolic risk profile similar to other ADT
- QT prolongation caution
Known or Plausible Interactions
- QT-prolonging medications (additive cardiac risk with hypogonadism)
- Anticoagulants (intramuscular injection site bleeding risk)
- Other androgen deprivation agents (not typically combined)
Regulatory Context
Plenaxis received FDA approval in 2003 under a restricted program but was discontinued and is no longer marketed in the United States. Abarelix therefore has historical FDA approval, not a currently available FDA-approved product. Its immediate systemic allergic-reaction risk was a major limitation.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | Historical FDA Approval |
| Best supported outcomes | Rapid Testosterone Suppression (Level A), Prostate Cancer Disease Control (Level A), and Allergic Reaction Risk (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Abarelix?
Abarelix safety concerns are compound-specific. The main listed side effects are Immediate-onset allergic reactions (3.7%), Hot flashes, and Sleep disturbances. The main warning signals are Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring, Available only through restricted distribution program due to allergy risk, and Bone density loss with prolonged androgen deprivation.
What is the evidence level for Abarelix?
Abarelix is rated Level A. Its current research status is Historical FDA Approval.
What is Abarelix best known for?
Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols.
Where can I read the full Abarelix evidence review?
The full evidence review is available at https://examinepeptides.com/library/abarelix.
Related Guides
How to Cite This Page
ExaminePeptides. "Abarelix Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/abarelix-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.